Enhanced Expression of Interleukin-6 in Bone and Serum of Metastatic Renal Cell Carcinoma

Overview

Journal Hum Pathol

Specialty Pathology

Date 1998 May 1

PMID 9563797

Citations 8

Authors

B Paule

D Clerc

C Rudant

C Coulombel

L Bonhomme-Faivre

J Quillard

M Bisson

Affiliations

Soon will be listed here.

Abstract

Interleukin-6 (IL-6) is produced by renal cell carcinoma (RCC) cell lines and primary tumors. Using immunohistochemical staining in two RCC patients with hypercalcemia and high serum levels of free and total IL-6, we showed expression of IL-6 in metastatic bone tissue. The role of IL-6 in hypercalcemia and bone resorption would suggest that bisphosphonates or dexamethasone could be useful as adjuvant therapy for IL-6 dependent bone metastases which fail to respond to interferon alpha (IFN) alpha 2a and all trans retinoic acid (ATRA).

Citing Articles

New players in the landscape of renal cell carcinoma bone metastasis and therapeutic opportunities.

Cesana B, Cochet C, Filhol O Int J Cancer. 2024; 156(3):475-487.

PMID: 39306698 PMC: 11622000. DOI: 10.1002/ijc.35181.

RKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity.

Touboul R, Baritaki S, Zaravinos A, Bonavida B Cancers (Basel). 2021; 13(24).

PMID: 34944867 PMC: 8699197. DOI: 10.3390/cancers13246247.

G3BP1 promotes tumor progression and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal cell carcinomas.

Wang Y, Fu D, Chen Y, Su J, Wang Y, Li X Cell Death Dis. 2018; 9(5):501.

PMID: 29717134 PMC: 5931548. DOI: 10.1038/s41419-018-0504-2.

Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.

Kawano Y, Takahashi W, Eto M, Kamba T, Miyake H, Fujisawa M Cancer Sci. 2016; 107(7):1013-7.

PMID: 27089226 PMC: 4946720. DOI: 10.1111/cas.12951.

RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients.

Cross-Knorr S, Lu S, Perez K, Guevara S, Brilliant K, Pisano C BMC Cancer. 2013; 13:463.

PMID: 24098947 PMC: 3856511. DOI: 10.1186/1471-2407-13-463.